Some strains of the avian H7N9 influenza that emerged in China this year have developed resistance to the only antiviral drugs available to treat the infection, but testing for antiviral resistance can give misleading results, ...
Jul 16, 2013
0
0
(HealthDay)—With the height of flu season here, the U.S Food and Drug Administration warns consumers to avoid fraudulent products that claim to prevent, treat or cure the flu.
Feb 4, 2013
0
0
(Medical Xpress)—Armed with data on vaccine effectiveness from five study monitoring sites, including one at the University of Michigan School of Public Health, the Centers for Disease Control is renewing the call for everyone ...
Jan 14, 2013
0
0
(HealthDay)—Flu season descended on the United States early and hard this winter, with significant increases in flu activity observed over the past month, according to an update issued Jan. 4 by the U.S. Centers for Disease ...
Jan 5, 2013
1
0
Incomplete availability of data has hampered a thorough assessment of the evidence for using the anti-influenza drug oseltamivir, a Cochrane Review has found. However, after piecing together information from over 16,000 pages ...
Jan 18, 2012
0
0
Zanamivir (INN) (pronounced /zəˈnæmɨvɪr/) is a neuraminidase inhibitor used in the treatment and prophylaxis of Influenzavirus A and Influenzavirus B. Zanamivir was the first neuraminidase inhibitor commercially developed. It is currently marketed by GlaxoSmithKline under the trade name Relenza.
This text uses material from Wikipedia, licensed under CC BY-SA
